Informations générales (source: ClinicalTrials.gov)

NCT05400590 En recrutement IDF
Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients (CICASAND)
Observational
  • Aniridie
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
mai 2023
septembre 2025
23 mai 2025
Keratopathy of patients with aniridia leads to epithelial scarring disorders and a progressive clouding of the cornea linked to this abnormal healing (fibrosis). Treatment with autologous serum is usually undertaken to promote epithelial healing. However, autologous serum does not prevent the formation of fibrosis, whereas growth factor-rich plasma appears to be associated with a reduction in the in vitro expression of fibrosis markers. This study seeks to compare the in vitro healing and anti-fibrotic properties of autologous serum and growth factor rich plasma from aniridia patients and healthy controls.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
HOPITAL FONDATION A. DE ROTHSCHILD Damien GUINDOLET En recrutement IDF 21/06/2024 13:34:39  Contacter

Critères

Tous
Inclusion Criteria:

For patients with aniridia:

- With aniridia

- Patient weighing more than 43 kg

- If the patient is being treated with autologous serum, a delay of 8 weeks after the
last blood collection

- If a blood donation has been made, a delay of 8 weeks must be respected after the
last donation

For controls:

- Non-aniridia (no clinical signs)

- Weighing more than 43 kg

- Matched to a case for sex and age +/-10 years

- No known diabetes

- If a blood donation has been made, a delay of 8 weeks must be respected after the
latter



- Insufficient sample volume

- No conjunctival print

- HBV, HCV, HIV serology positive

- Aniridia not genetically confirmed for cases For each patient excluded, a new
patient will be included in order to maintain the number of patients required for
data analysis.